A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: DB-1303/BNT323|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-paclitaxel
Sponsor: DualityBio Inc.
Collaborators: BioNTech SE